Daniel Gruener

541 total citations
15 papers, 307 citations indexed

About

Daniel Gruener is a scholar working on Hepatology, Infectious Diseases and Epidemiology. According to data from OpenAlex, Daniel Gruener has authored 15 papers receiving a total of 307 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Hepatology, 5 papers in Infectious Diseases and 4 papers in Epidemiology. Recurrent topics in Daniel Gruener's work include Hepatitis C virus research (6 papers), HIV/AIDS drug development and treatment (5 papers) and Immune Response and Inflammation (2 papers). Daniel Gruener is often cited by papers focused on Hepatitis C virus research (6 papers), HIV/AIDS drug development and treatment (5 papers) and Immune Response and Inflammation (2 papers). Daniel Gruener collaborates with scholars based in United States, Switzerland and Germany. Daniel Gruener's co-authors include Carrie Winterowd, Aaron T. Beck, John M. Hill, Eric Lawitz, John G. McHutchison, Thomas Marbury, Guofeng Cheng, John O. Link, Anita Mathias and Diana M. Brainard and has published in prestigious journals such as SHILAP Revista de lepidopterología, Hepatology and Journal of Hepatology.

In The Last Decade

Daniel Gruener

15 papers receiving 297 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Gruener United States	9	165	155	69	44	35	15	307
Nayra Rodríguez Puerto Rico	9	42 0.3×	97 0.6×	85 1.2×	25 0.6×	51 1.5×	21	320
Dong Kee Kim South Korea	12	97 0.6×	118 0.8×	13 0.2×	24 0.5×	54 1.5×	19	458
Valgerður Rúnarsdóttir Iceland	12	138 0.8×	219 1.4×	36 0.5×	23 0.5×	49 1.4×	25	372
Jörg Gölz Germany	9	66 0.4×	162 1.0×	45 0.7×	23 0.5×	119 3.4×	18	260
Daniel Tracy United States	7	85 0.5×	156 1.0×	39 0.6×	14 0.3×	49 1.4×	9	359
Michael Murphy United States	9	23 0.1×	39 0.3×	26 0.4×	36 0.8×	14 0.4×	23	238
Andreea Adelina Artenie Canada	13	203 1.2×	330 2.1×	105 1.5×	16 0.4×	106 3.0×	36	438
I.F.A. Hesse Ghana	8	103 0.6×	188 1.2×	85 1.2×	10 0.2×	10 0.3×	10	383
Anna Maria Spera Italy	9	69 0.4×	92 0.6×	66 1.0×	8 0.2×	13 0.4×	20	224
M Lyons United Kingdom	9	159 1.0×	221 1.4×	64 0.9×	5 0.1×	49 1.4×	12	309

Countries citing papers authored by Daniel Gruener

Since Specialization

Citations

This map shows the geographic impact of Daniel Gruener's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Gruener with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Gruener more than expected).

Fields of papers citing papers by Daniel Gruener

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Gruener. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Gruener. The network helps show where Daniel Gruener may publish in the future.

Co-authorship network of co-authors of Daniel Gruener

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Gruener. A scholar is included among the top collaborators of Daniel Gruener based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Gruener. Daniel Gruener is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Umbricht, Daniel, Markus Abt, Christopher H. Chatham, et al.. (2021). Proof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms. SHILAP Revista de lepidopterología. 1(1). 70–77. 9 indexed citations

Umbricht, Daniel, Juergen Dukart, Markus Abt, et al.. (2018). S43. A PROOF-OF-MECHANISM STUDY OF THE PDE10 INHIBITOR RG7203 IN PATIENTS WITH PROBING REWARD FUNCTIONS WITH IMAGING AND BEHAVIORAL APPROACHES. Schizophrenia Bulletin. 44(suppl_1). S340–S341. 2 indexed citations

Webster, Lynn R., et al.. (2016). Evaluation of the Tolerability of Switching Patients on Chronic Full μ-Opioid Agonist Therapy to Buccal Buprenorphine. Pain Medicine. 17(5). 899–907. 32 indexed citations

Vince, Bradley, John M. Hill, Eric Lawitz, et al.. (2014). A randomized, double-blind, multiple-dose study of the pan-genotypic NS5A inhibitor samatasvir in patients infected with hepatitis C virus genotype 1, 2, 3 or 4. Journal of Hepatology. 60(5). 920–927. 19 indexed citations

Lawitz, Eric, Daniel Gruener, Thomas Marbury, et al.. (2014). Safety, Pharmacokinetics and Pharmacodynamics of the Oral Toll-Like Receptor 7 Agonist GS-9620 in Treatment-Naive Patients with Chronic Hepatitis C. Antiviral Therapy. 20(7). 699–708. 27 indexed citations

Lawitz, Eric, John M. Hill, Bradley Vince, et al.. (2013). 847 ACH-2684 DEMONSTRATES POTENT VIRAL SUPPRESSION IN GENOTYPE 1 HEPATITIS C PATIENTS WITH AND WITHOUT CIRRHOSIS: SAFETY, PHARMACOKINETIC, AND VIRAL KINETIC ANALYSIS. Journal of Hepatology. 58. S347–S347. 5 indexed citations

Jin, Ling, Wen Xu, Daniel Gruener, et al.. (2013). Clinical Outcomes from an Open-Label Study of Edivoxetine Use in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 23(3). 200–207. 9 indexed citations

Gane, Edward, Éric Sicard, Stuart C. Gordon, et al.. (2013). Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B. Hepatology. 58. 4 indexed citations

Vourvahis, Manoli, Rong Wang, Daniel Gruener, et al.. (2012). Effect of lersivirine co-administration on pharmacokinetics of methadone in healthy volunteers. Drug and Alcohol Dependence. 126(1-2). 183–188. 8 indexed citations

10.

Lawitz, E.J., Jacqueline Hill, Lydie Hazan, et al.. (2012). 1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS. Journal of Hepatology. 56. S470–S471. 7 indexed citations

11.

Lawitz, Eric, Daniel Gruener, John M. Hill, et al.. (2012). A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. Journal of Hepatology. 57(1). 24–31. 120 indexed citations

12.

Läwitz, E., Lydie Hazan, Daniel Gruener, et al.. (2012). 1189 GS-9669, A NOVEL NS5B NON-NUCLEOTIDE SITE II INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY, FAVORABLE SAFETY PROFILE AND POTENTIAL FOR ONCE-DAILY DOSING. Journal of Hepatology. 56. S471–S471. 5 indexed citations

13.

Winterowd, Carrie, Aaron T. Beck, & Daniel Gruener. (2004). Cognitive Therapy with Chronic Pain Patients. Pain Practice. 4(1). 67–67. 47 indexed citations

14.

Gruener, Daniel, et al.. (1997). Sequelae of sexual assault. Primary Care Update for OB/GYNS. 4(4). 143–146. 9 indexed citations

15.

Gruener, Daniel, et al.. (1994). Dietary vitamin B12 deficiency in a patient with multiple sclerosis. General Hospital Psychiatry. 16(3). 224–228. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact